666P Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients
| Autor: | Blagden, S. 1, Elshani, M. 2, Symeonides, S.N. 3, Skolariki, A. 1, Haris, N.R. 4, Boh, Z.Y. 3, Dickson, A. 2, Um, I.H. 2, Zhang, Y. 2, McKissock, F.G. 5, Oelmann, E. 5, Bloss, J. 5, Cook, N. 6, Evans, T.R.J. 7, Plummer, R. 4, Harrison, D.J. 2 |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S523-S524 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|